Free Newsletter
For security, Pfizer watches suppliers
"Do not enter into supply agreements with companies that do not meet acceptable standards, and terminate agreements with companies that do not maintain acceptable standards." So says Gerry Migliaccio, senior VP for global manufacturing at Pfizer, in a Pharmaceutical Technology interview.
He says that's an oversimplification of one of the key elements of enforcement in a strategy for supply-chain security. Many factors are involved in evaluating suppliers, notes Migliaccio. But once basic viability has been established, he looks at their quality systems and environmental-management systems.
Migliaccio also notes in the interview that control of the suppliers to Pfizer's suppliers is among then most critical of supply chain security issues.
- see the article
Related Article:
Pfizer quick with sword
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: